- Home
- ROIV vs DCI Comparison
ROIV vs DCI Comparison
Compare ROIV & DCI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ROIV
- DCI
- Stock Information
- Founded
- ROIV 2014
- DCI 1915
- Country
- ROIV United Kingdom
- DCI United States
- Employees
- ROIV N/A
- DCI N/A
- Industry
- ROIV Biotechnology: Pharmaceutical Preparations
- DCI Pollution Control Equipment
- Sector
- ROIV Health Care
- DCI Industrials
- Exchange
- ROIV Nasdaq
- DCI Nasdaq
- Market Cap
- ROIV 8.4B
- DCI 7.9B
- IPO Year
- ROIV N/A
- DCI 1987
- Fundamental
- Price
- ROIV $10.67
- DCI $69.73
- Analyst Decision
- ROIV Buy
- DCI Hold
- Analyst Count
- ROIV 4
- DCI 4
- Target Price
- ROIV $17.50
- DCI $71.33
- AVG Volume (30 Days)
- ROIV 5.9M
- DCI 461.7K
- Earning Date
- ROIV 05-29-2025
- DCI 06-03-2025
- Dividend Yield
- ROIV N/A
- DCI 1.55%
- EPS Growth
- ROIV N/A
- DCI 11.79
- EPS
- ROIV N/A
- DCI 3.42
- Revenue
- ROIV $122,585,000.00
- DCI $3,633,400,000.00
- Revenue This Year
- ROIV N/A
- DCI $2.95
- Revenue Next Year
- ROIV N/A
- DCI $3.44
- P/E Ratio
- ROIV N/A
- DCI $20.40
- Revenue Growth
- ROIV 140.04
- DCI 4.46
- 52 Week Low
- ROIV $8.73
- DCI $57.45
- 52 Week High
- ROIV $13.06
- DCI $78.95
- Technical
- Relative Strength Index (RSI)
- ROIV 47.82
- DCI 64.33
- Support Level
- ROIV $10.58
- DCI $65.72
- Resistance Level
- ROIV $11.77
- DCI $70.80
- Average True Range (ATR)
- ROIV 0.34
- DCI 0.99
- MACD
- ROIV -0.07
- DCI 0.62
- Stochastic Oscillator
- ROIV 7.56
- DCI 83.66
About ROIV Roivant Sciences Ltd.
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.
About DCI Donaldson Company Inc.
Donaldson is a leading manufacturer of filtration systems and replacement parts (including air filtration systems, liquid filtration systems, and dust, fume, and mist collectors). The company serves a diverse range of end markets, including construction, mining, agriculture, truck, and industrial. Its business is organized into three segments: mobile solutions, industrial solutions, and life sciences. Donaldson generated approximately $3.6 billion in revenue and $544 million in operating income in its fiscal 2024.